Ra Capital Management, L.P. Macrogenics Inc Transaction History

Ra Capital Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.31 - $18.51 $6.89 Million - $38.5 Million	2,082,021 New	2,082,021 $8.85 Million
Q1 2024 May 15, 2024	SELL	$9.77 - $21.47 $19.3 Million - $42.3 Million	-1,971,056 Reduced 48.63%	2,082,021 $30.6 Million
Q4 2023 Feb 14, 2024	BUY	$4.48 - $10.11 $18.2 Million - $41 Million	4,053,077 New	4,053,077 $39 Million
Q3 2023 Nov 14, 2023	BUY	$4.48 - $6.19 $1.53 Million - $2.12 Million	342,000 New	342,000 $1.59 Million
Q2 2022 Aug 15, 2022	SELL	$2.25 - $9.99 $13.7 Million - $61 Million	-6,103,594 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.91 - $21.88 $2.55 Million - $3.5 Million	160,000 Added 2.69%	6,103,594 $98 Million
Q2 2021 Aug 16, 2021	BUY	$20.49 - $35.63 $20.7 Million - $36 Million	1,010,000 Added 20.47%	5,943,594 $160 Million
Q1 2021 May 17, 2021	BUY	$18.99 - $33.2 $10.6 Million - $18.5 Million	558,377 Added 12.76%	4,933,594 $157 Million
Q3 2020 Nov 16, 2020	SELL	$24.69 - $31.6 $5.17 Million - $6.62 Million	-209,435 Reduced 4.57%	4,375,217 $110 Million
Q2 2020 Aug 14, 2020	BUY	$5.2 - $29.12 $23.8 Million - $134 Million	4,584,652 New	4,584,652 $128 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.